Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06978725 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
A Phase 2 study of Cutaneous Sarcoidosis, sponsored by Priovant Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT06978725: Recruiting Phase 2 study of Cutaneous Sarcoidosis, sponsored by Priovant Therapeutics.
NCT06978725 is a Phase 2 study of Cutaneous Sarcoidosis that is actively recruiting participants, run by Priovant Therapeutics. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06978725, a Phase 2 study of Cutaneous Sarcoidosis, is actively recruiting participants, sponsored by Priovant Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Conditions Studied
Interventions
- DRUG Oral Brepocitinib
- DRUG Oral Placebo
Study Locations (4)
California
- Clinical Trial Site - San Francisco
North Carolina
- Clinical Trial Site - Durham
Pennsylvania
- Clinical Trial Site - Philadelphia
Wisconsin
- Clinical Trial Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06978725 shows while recruiting
NCT06978725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Cutaneous Sarcoidosis appearing as the primary indexed condition, and to 2 interventions - of which Oral Brepocitinib is the first listed.
NCT06978725 reports a single indexed study location in California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06978725 about?
NCT06978725 is a clinical study titled "A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)". This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
What is the current status of trial NCT06978725?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-04-09. Estimated completion is 2026-12.
What conditions does trial NCT06978725 study?
This clinical trial studies the following conditions: Cutaneous Sarcoidosis.
What interventions are being tested in trial NCT06978725?
The interventions under investigation include: Oral Brepocitinib (DRUG), Oral Placebo (DRUG).
Who is sponsoring clinical trial NCT06978725?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06978725 being conducted?
This trial has 4 study locations across California, North Carolina, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06978725's enrollment target sits among peer trials
28 1677th of 2000 higher than 305 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI